![]() Collectively, donepezil administration resulted in rapid recovery of cognitive ability within a week, which started to decline gradually over the course of the drug administration. ![]() Quantification analyses showed that area but not number of Aβ plaques were decreased ( P = 0.0072, and P = 0.0115, respectively) compared to non-treated APP/PS1 mice, suggesting that donepezil exhibits weak inhibitory effect against Aβ aggregation. EPPS was previously reported to directly disaggregate Aβ oligomers and plaques back into inert monomers in the brains of APP/PS1 mice. ![]() This mouse model produces elevated levels of human Aβ by expressing mutant human APP and PS1, which leads to development of Aβ plaques and AD-like cognitive impairments from 6 months of age. Herein, we administered 4-(2-hydroxyethyl)-1-piperazinepropanesulphonic acid (EPPS), for its disease-modifying effect, and donepezil, for its symptomatic relief, together to aged APPswe/PS1-dE9 (amyloid precursor protein/presenilin protein 1) mice (APP/PS1). We hypothesized that a combination of anti-amyloid and anti-acetylcholinesterase therapeutic strategies would complement each other and result in a relatively prompt symptom improvement along with Aβ clearance taking place in the Alzheimer brain with a sustained symptomatic control owing to the action of the disease-modifying drug. ![]() Thus, both disease-modifying and symptomatic relief drugs are necessary as an intervention to effectively treat AD. Nonetheless, brain atrophy associated with cognitive deficits could not be recovered by modulating pathological culprits. ![]()
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |